Blocking FSH inhibits hepatic cholesterol biosynthesis and reduces serum cholesterol

• 来源期刊: 细胞研究（英文版）
• 年，卷（期）: 2019,（2）
• 页码范围: 151-166
• 页数: 16页
• 语种: 英文

摘要

Menopause is associated with dyslipidemia and an increased risk of cardio-cerebrovascular disease.The classic view assumes that the underlying mechanism of dyslipidemia is attributed to an insufficiency of estrogen.In addition to a decrease in estrogen,circulating follicle-stimulating hormone (FSH) levels become elevated at menopause.In this study,we find that blocking FSH reduces serum cholesterol via inhibiting hepatic cholesterol biosynthesis.First,epidemiological results show that the serum FSH levels are positively correlated with the serum total cholesterol levels,even after adjustment by considering the effects of serum estrogen.In addition,the prevalence of hypercholesterolemia is significantly higher in peri-menopausal women than that in premenopausal women.Furthermore,we generated a mouse model of FSH elevation by intraperitoneally injecting exogenous FSH into ovariectomized (OVX) mice,in which a normal level of estrogen (E2) was maintained by exogenous supplementation.Consistently,the results indicate that FSH,independent of estrogen,increases the serum cholesterol level in this mouse model.Moreover,blocking FSH signaling by anti-FSHβ antibody or ablating the FSH receptor (FSHR) gene could effectively prevent hypercholesterolemia induced by FSH injection or high-cholesterol diet feeding.Mechanistically,FSH,via binding to hepatic FSHRs,activates the Gi2α/β-arrestin-2/Akt pathway and subsequently inhibits the binding of FoxO1 with the SREBP-2 promoter,thus preventing FoxO1 from repressing SREBP-2 gene transcription.This effect,in turn,results in the upregulation of SREBP-2,which drives HMGCR nascent transcription and de novo cholesterol biosynthesis,leading to the increase of cholesterol accumulation.This study uncovers that blocking FSH signaling might be a new strategy for treating hypercholesterolemia during menopause,particularly for women in peri-menopause characterized by FSH elevation only.